The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes

This publication has 30 references indexed in Scilit:

• Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea
  Translational Research, 2012
• Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
  Trends in Pharmacological Sciences, 2009
• Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme
  Current Medicinal Chemistry, 2009
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
  Pharmacological Reviews, 2008
• The Physiology of Glucagon-like Peptide 1
  Physiological Reviews, 2007
• Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
  European Journal of Endocrinology, 2006
• Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
  Diabetologia, 2005
• Circulating CD26 Is Negatively Associated with Inflammation in Human and Experimental Arthritis
  The American Journal of Pathology, 2005
• Molecular characterization of dipeptidyl peptidase activity in serum
  European Journal of Biochemistry, 2000
• Dipeptidyl Peptidase IV from Human Serum: Purification, Characterization, and N-Terminal Amino Acid Sequence
  The Journal of Biochemistry, 1998